Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
IPIX INNOVATION PHARMACEUTICALS INC
0.0200.0000.00%
Close
02/03 16:00 ET
High
0.020
Open
0.020
Turnover
4.56K
Low
0.019
Pre Close
0.020
Volume
229.71K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
BT BeaMedical, Shina Systems Enter Strategic Development Agreement
Innovation Pharmaceuticals Announces BT BeaMedical Technologies and Shina Systems Ltd. Enter Into a Definitive Strategic Development Agreement
Multiyear Development and Support Agreement Lays the Foundation for the Realization of an Advanced Software Suite to Enable Revolutionary Treatments of Epilepsy and Brain Tumors WAKEFIELD, MA, Jan. 0
Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin's Potential for Treating Fungal Keratitis
Additionally, Brilacidin to be Screened by NIH/NIAID to Further Characterize Its Broad-Spectrum Antifungal Activity WAKEFIELD, MA, Dec. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Innovation Pharmaceuticals
Innovation Pharmaceuticals Announces BT BeaMedical Technologies Receives FDA Clearance for New Surgical Laser Family
Regulatory clearance lays key technological and regulatory foundation for BT BeaMedical's vision of revolutionizing treatment options in neurosurgery, oncology, and a wide spectrum of other clinical s
NHS Medical Director for Specialised Services Calls New Laser Technology for Epilepsy "Game-Changing Breakthrough"
Innovation Pharmaceuticals believes U.K. launch of MRgLITT for refractory focal epilepsy substantiates its investment in advanced laser technology of BT BeaMedical WAKEFIELD, MA, Oct. 26, 2022 (GLOB
Innovation Pharmaceuticals' Brilacidin Shows Efficacy in Antifungal Study
Innovation Pharmaceuticals Announces Publication of Scientific Article on the Antifungal Activity of Brilacidin
In pre-clinical studies, Brilacidin shown to synergize with marketed antifungals against pathogenic species of aspergillosis, candidiasis, cryptococcosis and mucormycosis, and further exhibited poten
New In Vitro Data Supporting the Broad-Spectrum Antiviral Activity of Innovation Pharmaceuticals' Brilacidin Presented at 2022 Military Health System Research Symposium
Brilacidin shown to inhibit multiple alphaviruses, the bunyavirus Rift Valley Rift Fever, and Echovirus (a non-enveloped picornavirus)WAKEFIELD, MA / ACCESSWIRE / September 15, 2022 / Innovation Pharm
Innovation Pharmaceuticals' Investment in BT BeaMedical Helping Advance New Surgical Laser Platform
WAKEFIELD, MA / ACCESSWIRE / September 13, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today updated shareholders on recent progress by
Innovation Pharmaceuticals: Researchers to evaluate brilacidin against monkeypox
Innovation Pharmaceuticals announced that Brilacidin is to be evaluated for its treatment potential against the monkeypox virus.To establish potential proof-of-concept, in vitro testing initially will
Company Overview
More
Innovation Pharmaceuticals, Inc. is a clinical stage biotechnology company. It engages in developing therapies with anti-infective, oncology, anti-inflammatory and dermatology applications. The firm's lead cancer compound, Kevetrin, is an anti-cancer drug which has demonstrated the ability in pre-clinical studies to regulate the p53 pathway and attack cancers. The company was founded by Krishna Kumar Menon and Leo Ehrlich in June 20, 2007 and is headquartered in Wakefield, MA.
CEO： --
Market： Pink Market
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet